Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

62.42USD
8 Dec 2017
Change (% chg)

$0.58 (+0.94%)
Prev Close
$61.84
Open
$61.82
Day's High
$62.72
Day's Low
$61.68
Volume
5,309,959
Avg. Vol
5,494,180
52-wk High
$66.10
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Announces 2.6 Pct Increase In Quarterly Dividend Beginning Q1 2018
Thursday, 7 Dec 2017 04:15pm EST 

Dec 7 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND INCREASE.BRISTOL-MYERS SQUIBB CO - AN INCREASE OF 2.6% PERCENT IN COMPANY'S QUARTERLY DIVIDEND, BEGINNING IN Q1 OF 2018.BRISTOL-MYERS SQUIBB CO - DIVIDEND INCREASE WILL RESULT IN A QUARTERLY DIVIDEND OF 40 CENTS.  Full Article

Ayala Enters Exclusive Worldwide License Agreement With Bristol-Myers Squibb
Wednesday, 6 Dec 2017 09:30am EST 

Dec 6 (Reuters) - Ayala Pharmaceuticals::AYALA PHARMACEUTICALS, FOUNDED BY ISRAEL BIOTECH FUND, AMOON AND HAREL INSURANCE, ENTERS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB (BMS) TO DEVELOP CANCER TREATMENTS.‍SAYS WILL HAVE EXCLUSIVE WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS FOR BMS-906024 AND BMS-986115​.SAYS CO IS RESPONSIBLE FOR ALL FUTURE DEVELOPMENT AND COMMERCIALIZATION OF BMS-906024 AND BMS-986115.SAYS IN CONNECTION WITH LICENSE, BMS RECEIVED UPFRONT PAYMENT, BECAME A SHAREHOLDER OF CO.SAYS ‍PLAN TO INITIATE PHASE 2 CLINICAL TRIALS IN 2018​.SAYS IN CONNECTION WITH LICENSE, BMS TO ALSO RECEIVE CERTAIN DEVELOPMENT, REGULATORY, SALES-BASED MILESTONES, TIERED ANNUAL NET SALES ROYALTIES.  Full Article

Bristol-Myers says Checkmate -078 trial stopped early for demonstrating superior overall survival
Thursday, 30 Nov 2017 07:00pm EST 

Nov 30 (Reuters) - Bristol-Myers Squibb Co ::CHECKMATE -078, A PIVOTAL, MULTINATIONAL PHASE 3 OPDIVO (NIVOLUMAB) LUNG CANCER TRIAL WITH PREDOMINANTLY CHINESE PATIENTS, STOPPED EARLY FOR DEMONSTRATING SUPERIOR OVERALL SURVIVAL.‍CHINA FOOD AND DRUG ADMINISTRATION ACCEPTED MARKETING APPLICATION FOR OPDIVO​.‍SAFETY PROFILE OF OPDIVO WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES IN SOLID TUMORS​.BRISTOL-MYERS- OPDIVO SHOWS SUPERIOR OVERALL SURVIVAL COMPARED TO DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER​.  Full Article

Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic
Tuesday, 28 Nov 2017 08:30am EST 

Nov 28 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC.CYTOMX THERAPEUTICS INC - ‍IND ACCEPTANCE RESULTS IN A $10 MILLION MILESTONE PAYMENT TO CYTOMX​.CYTOMX THERAPEUTICS INC - ‍BRISTOL-MYERS SQUIBB HAS RECEIVED ACCEPTANCE OF IND FROM U.S. FDA FOR A CTLA-4-DIRECTED PROBODY THERAPEUTIC​.  Full Article

Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo
Wednesday, 15 Nov 2017 08:45am EST 

Nov 15 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo®.Laboratory Corporation Of America Holdings - ‍announced U.S. availability of PD-L1 ihc 28-8 pharmdx assay as complementary diagnostic for 2 indications in connection with use of Opdivo​.  Full Article

Bristol-Myers and Syngene expand ongoing research collaboration
Tuesday, 14 Nov 2017 09:44am EST 

Nov 14 (Reuters) - Syngene International ::Bristol-Myers Squibb and Syngene International expand ongoing research collaboration.Says collaboration with Bristol-Myers Squibb extended until 2026​.  Full Article

Syngene International ‍expands collaboration with Bristol-Myers Squibb​
Monday, 13 Nov 2017 10:06pm EST 

Nov 14 (Reuters) - Syngene International Ltd ::Says ‍expanded collaboration with Bristol-Myers Squibb​.Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​.  Full Article

Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study
Friday, 10 Nov 2017 07:00am EST 

Nov 10 (Reuters) - Bristol-myers Squibb Co :Encouraging response observed with Opdivo (nivolumab) plus investigational ido1 inhibitor, BMS-986205, in heavily pre-treated patients with advanced cancers in phase 1/2a study ca017-003.Bristol-Myers Squibb Co - ‍In dose escalation phase, maximum tolerated dose (primary endpoint) of BMS-986205 in combination with Opdivo was 200mg​.  Full Article

U.S. Food and Drug Administration expands approval of Sprycel (dasatinib)
Friday, 10 Nov 2017 06:30am EST 

Nov 10 (Reuters) - Bristol-myers Squibb Co ::U.S. Food and Drug Administration expands approval of Sprycel (dasatinib) to include treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.Approval based on data from prospective trial in pediatric chronic myeloid leukemia in chronic phase​.Co says ‍continues to explore pediatric applications for investigational oncology agents within its broad development program​.Approval for Sprycel granted under priority review, indication received Orphan Drug Designation from FDA.  Full Article

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Merck raises stakes in lung cancer as rivals close in

LOS ANGELES Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.